Retatrutide vs Qsymia: New vs Old Technology
Retatrutide (peptide, 24-28% loss) vastly outperforms Qsymia (phentermine/topiramate, 8-10% loss). Peptides are the future.
| Feature | Retatrutide | Qsymia |
|---|---|---|
| Weight Loss | 24-28.7% | 8-10% |
| Mechanism | Triple agonist peptide | Stimulant + anticonvulsant |
| Delivery | Weekly injection | Daily oral pill |
| Side Effects | GI symptoms (nausea) | Increased heart rate, insomnia, tingling |
Why Qsymia Is Being Replaced by Peptides
Qsymia (2012) was cutting-edge... 14 years ago. GLP-1 peptides have made it mostly obsolete:
- • 2-3x less effective: 8-10% vs 24-28% with retatrutide
- • Stimulant-based: Phentermine increases heart rate/blood pressure (concerning for some patients)
- • More contraindications: Can't use with heart disease, glaucoma, hyperthyroidism
- • Birth defect risk: Topiramate causes cleft palate (absolute contraindication in pregnancy)
When Qsymia makes sense: Only if you can't afford peptides and have no cardiovascular issues.
Upgrade to Modern Peptides
Tirzepatide: 15-22.5% loss (2x better than Qsymia), safer profile, $179-499/mo.
Start Tirzepatide →